• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Exelixis

Exelixis

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Ipsen and its partner Exelixis announce independent radiology committee review confirms results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell ...

    Ipsen and its partner Exelixis announce independent radiology committee review confirms results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma

  2. Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors

    Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors

  3. Is This the Year Exelixis Excels?

    The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.

  4. Don't Bail on Biotech

    We see opportunity as fleeing investors trigger an irrational sell-off.

  5. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

  6. Beware 5-Star Stocks Bearing No Moats

    Lack of competitive advantages may mean these companies aren't the bargains they seem to be.

  7. Biotech ETFs: Which One Is Best Now?

    The five biotech ETFs have very different portfolios with markedly different performance.

©2017 Morningstar Advisor. All right reserved.